{"doi":"10.1200/op-24-00809","title":"Video Education Is an Acceptable Alternative to Pretest Genetic Counseling for Patients With Breast, Ovarian, Pancreatic, and Metastatic Prostate Cancer: Results From a Randomized Study","abstract":"<jats:sec>\n                    <jats:title>PURPOSE</jats:title>\n                    <jats:p>With increased demand for cancer genetic testing (GT), providers are exploring alternative service delivery models such as video education (VE). We compare the uptake of GT among 250 patients with breast, ovarian, pancreatic, or metastatic prostate cancer randomly assigned to receive either pretest VE or a pretest visit with a genetic counselor (GC).</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS</jats:title>\n                    <jats:p>Using a 3:1 ratio, 187 patients were randomly assigned to the VE arm and 63 patients to the GC arm. GT was arranged after participants either watched an informative video (VE arm) or met with a GC (GC arm). Satisfaction, knowledge, distress, decisional regret, and family communication were assessed as secondary study end points.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS</jats:title>\n                    <jats:p>\n                      Participants were age 39-88 years with no significant demographic differences between the two arms. In the VE arm, 170 (90.95%) participants completed GT versus 49 (77.8%) in the GC arm (\n                      <jats:italic toggle=\"yes\">P</jats:italic>\n                      = .01). The dropout rate before the pretest visit was higher in the GC arm compared with the VE arm: 10 (15.9%) versus 9 (4.8%). In the GC arm, 97.4% of participants felt all questions and concerns had been addressed compared with 66.9% of the VE arm (\n                      <jats:italic toggle=\"yes\">P</jats:italic>\n                      &lt; .0001). Of the 219 participants tested, 29 (13.2%) had a pathogenic or likely pathogenic variant.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION</jats:title>\n                    <jats:p>In this study, there was high acceptance of VE and it led to better GT uptake compared with the GC arm. However, it will be important for programs using VE to build-in more opportunities for patients to ask questions. Pretest VE is a viable option for patients with cancer who need their germline genetic test results to help guide surgical and medical decisions.</jats:p>\n                  </jats:sec>","journal":"JCO Oncology Practice","year":2025,"id":635892,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1110120,"name":"Lauren Massingham","orcid":"0000-0002-2497-1552","position":1,"is_corresponding":false},{"id":558208,"name":"Michelle Weitz","orcid":null,"position":2,"is_corresponding":false},{"id":445802,"name":"Chanika Phornphutkul","orcid":"0000-0002-0130-9101","position":3,"is_corresponding":false},{"id":1649996,"name":"Melissa Leach","orcid":null,"position":4,"is_corresponding":false},{"id":570400,"name":"Shraddha Gaonkar","orcid":null,"position":5,"is_corresponding":false},{"id":1313654,"name":"Jennifer Schwab","orcid":"0009-0004-7193-3884","position":6,"is_corresponding":false},{"id":1649997,"name":"Hannah Pepprock","orcid":null,"position":7,"is_corresponding":false},{"id":1359779,"name":"Alexander Husband","orcid":"0009-0000-6033-529X","position":8,"is_corresponding":false},{"id":1649998,"name":"Jeanna Walsh","orcid":null,"position":9,"is_corresponding":false},{"id":1649999,"name":"Michael Constantine","orcid":null,"position":10,"is_corresponding":false},{"id":1650000,"name":"Meredith Faggen","orcid":null,"position":11,"is_corresponding":false},{"id":1650001,"name":"Olga Kozyreva","orcid":"0000-0001-7202-7972","position":12,"is_corresponding":false},{"id":1650002,"name":"Kerry Kilbridge","orcid":null,"position":13,"is_corresponding":false},{"id":95411,"name":"Judy E. Garber","orcid":"0000-0001-9449-3982","position":14,"is_corresponding":false},{"id":664939,"name":"Huma Q. Rana","orcid":"0000-0002-1598-6752","position":15,"is_corresponding":false},{"id":511136,"name":"Katherine A. Schneider","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Video Education Is an Acceptable Alternative to Pretest Genetic Counseling for Patients With Breast, Ovarian, Pancreatic, and Metastatic Prostate Cancer: Results From a Randomized Study","abstract":"<jats:sec>\n                    <jats:title>PURPOSE</jats:title>\n                    <jats:p>With increased demand for cancer genetic testing (GT), providers are exploring alternative service delivery models such as video education (VE). We compare the uptake of GT among 250 patients with breast, ovarian, pancreatic, or metastatic prostate cancer randomly assigned to receive either pretest VE or a pretest visit with a genetic counselor (GC).</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS</jats:title>\n                    <jats:p>Using a 3:1 ratio, 187 patients were randomly assigned to the VE arm and 63 patients to the GC arm. GT was arranged after participants either watched an informative video (VE arm) or met with a GC (GC arm). Satisfaction, knowledge, distress, decisional regret, and family communication were assessed as secondary study end points.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS</jats:title>\n                    <jats:p>\n                      Participants were age 39-88 years with no significant demographic differences between the two arms. In the VE arm, 170 (90.95%) participants completed GT versus 49 (77.8%) in the GC arm (\n                      <jats:italic toggle=\"yes\">P</jats:italic>\n                      = .01). The dropout rate before the pretest visit was higher in the GC arm compared with the VE arm: 10 (15.9%) versus 9 (4.8%). In the GC arm, 97.4% of participants felt all questions and concerns had been addressed compared with 66.9% of the VE arm (\n                      <jats:italic toggle=\"yes\">P</jats:italic>\n                      &lt; .0001). Of the 219 participants tested, 29 (13.2%) had a pathogenic or likely pathogenic variant.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION</jats:title>\n                    <jats:p>In this study, there was high acceptance of VE and it led to better GT uptake compared with the GC arm. However, it will be important for programs using VE to build-in more opportunities for patients to ask questions. Pretest VE is a viable option for patients with cancer who need their germline genetic test results to help guide surgical and medical decisions.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40209136","pmcid":"PMC12622282","openalex_id":"https://openalex.org/W4409318062","authors":[],"funders":[],"total_grants":0,"fwci":4.6982,"citation_percentile":0.94645064,"influential_citations":0,"citation_trend":[{"year":2025,"count":1},{"year":2026,"count":4}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://ascopubs.org/doi/pdf/10.1200/OP-24-00809","host_type":"journal"},{"url":"https://ascopubs.org/doi/pdf/10.1200/OP-24-00809","host_type":"publisher"},{"url":"https://ascopubs.org/doi/pdfdirect/10.1200/OP-24-00809","host_type":"publisher"},{"url":"https://doi.org/10.1200/op-24-00809","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40209136","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12622282","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12622282","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12622282?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["BRCA gene mutations in cancer","Genomics and Rare Diseases","Genetic factors in colorectal cancer","Humans","Male","Genetic Counseling","Female","Middle Aged","Aged","Adult","Prostatic Neoplasms","Pancreatic Neoplasms","Aged, 80 and over","Breast Neoplasms","Ovarian Neoplasms","Patient Education as Topic","Genetic Testing","Video Recording"],"mesh_terms":["Adult","Aged","Aged, 80 and over","Breast Neoplasms","Female","Genetic Counseling","Genetic Testing","Humans","Male","Middle Aged","Ovarian Neoplasms","Pancreatic Neoplasms","Patient Education as Topic","Prostatic Neoplasms","Video Recording"],"keywords":["Medicine","Prostate cancer","Pancreatic cancer","Breast cancer","Internal medicine","Oncology","Cancer","Gynecology","Physical therapy"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T15:46:09.770767Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}